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Edited by Felix WielandAbstract Sialylation (e.g. expression of sialic acid) plays a cru-
cial role for function and stability of most glycoproteins. The key
enzyme for the biosynthesis of sialic acid is the UDP-N-acetyl-
glucosamine 2-epimerase/N-acetylmannosamine-kinase (GNE).
Mutations in the binding site of the feedback inhibitor CMP-sia-
lic acid of the GNE leads to sialuria, a disease in which patients
produce sialic acid in gram scale. Here, we report on the use in
biotechnology of sialuria-mutated GNE. Expression of the sial-
uria-mutated GNE in CHO-cells leads to increased sialylation
of recombinant expressed erythropoietin (EPO). Our data show
that sialuria-mutated-GNE over-expressing cells are the perfect
platform to express highly sialylated therapeutic proteins, such
as EPO.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Recombinant glycoprotein1. Introduction
The number of recombinant glycoproteins used in therapy
has increased over the past years and many of the high-value
therapeutic proteins in the market today are glycoproteins.
Usually recombinant glycoproteins are produced in mamma-
lian cell lines to obtain mammalian-type glycosylation. This
is a major issue in biotechnology since glycan composition of
recombinant glycoproteins determines their biological func-
tions [1]. The terminal position of N-linked complex glycans
is typically occupied by sialic acid. Presence of sialic acid in-
crease the in vivo circulatory lifetime of glycoproteins as sialic
acid terminated glycans are not recognized by asialoglycopro-
tein receptors of hepatocytes [2–5]. In contrast, unsialylated
glycoproteins are recognized by the asialoglycoprotein recep-
tor via the exposed galactose and targeted for degradation
[6]. However, the sialylation of over-expressed glycoproteins
in mammalian cell lines like Chinese Hamster Ovary (CHO)
cells used for the production of therapeutic glycoproteins is*Corresponding author. Fax: +49 345 5573811.
E-mail address: ruediger.horstkorte@medizin.uni-halle.de (R. Horst-
korte).
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doi:10.1016/j.febslet.2007.07.060incomplete [7] and result in an objectionable heterogenic sialyl-
ation of the product.
The biosynthesis of sialic acid is regulated by the feedback
inhibition of the key enzyme of sialic acid biosynthesis, the
UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) [8]. GNE
is a bifunctional enzyme, which catalyzes the conversion of
UDP-GlcNAc to ManNAc and the phosphorylation of Man-
NAc to ManNAc-6-phosphate (see Fig. 1) [9,10]. The next step
is a condensation of ManNAc-6-P and pyruvat resulting in sia-
lic acid. Then, sialic acid is activated in the nucleus into the
nucleotide donor CMP-sialic acid [11,12]. CMP-sialic acid
inhibits GNE in a feedback dependent manner [13]. Several
approaches have been made to enhance sialylation and to max-
imize the yield of high quality glycoproteins for pharmaceutical
use. It has been suggested that insuﬃcient concentration of
CMP-sialic acid inside the trans-Golgi is the major cause for
incomplete intracellular sialylation in CHO-cells [12]. There-
fore, most approaches focus on an increased concentration of
CMP-sialic acid inside the trans-Golgi. To bypass the feedback
mechanism cells can be supplemented with ManNAc, which
intercept the pathway beyond the GNE (see Fig. 1). The supple-
mentation with ManNAc leads to an increased intracellular
concentration of sialic acid and to an increased sialylation of
recombinant glycoproteins in CHO cells [13]. Also the overex-
pression of the CMP-sialic acid golgi transporter and several
sialyltransferases slightly enhance the sialylation [14,15].
Sialuria is a rare inborn error of the sialic acid metabolism.
A defect of the feedback inhibition is caused by point muta-
tions within the epimerase domain of GNE (R263L, R266Q,
and R266W) leading to excessive synthesis of sialic acid [16].
We have previously shown that the expression of GNE-
R263L led to an increased polysialylation of the neural cell
adhesion molecule (NCAM) [17]. In this article, we will report
on the use of the GNE sialuria mutation to increase intracellu-
lar sialic acid concentration and to improve sialylation of re-
combinant glycoproteins. As a model system we have chosen
CHO-cells producing recombinant human erythropoietin
(rhEPO). EPO is a glycoprotein hormone that is a cytokine
for erythrocyte precursors [18]. It contains three complex type
N-glycans located on Asn residues at position 24, 38 and 83,
and an O-glycosylation site at position 126 [19] and has a max-
imum of 14 sialic acids per molecule (4 sialic acids molecules
on each tetra-antennary N-glycan and 2 sialic acids molecules
on the O-glycans). The sialylation is important for the biolog-
ical activity of EPO. Weak or non-sialylated EPO has a dra-
matically decreased biological activity due to the reduced
circulatory half-life [20,21].ation of European Biochemical Societies.
Fig. 1. Schematic representation of the sialic acid biosynthesis.
4196 K. Bork et al. / FEBS Letters 581 (2007) 4195–41982. Materials and methods
2.1. Generation of stable CHO-EPO cells expressing sialuria mutated
GNE
An GNE-sialuria expression vector, pcDNA3.1-GNE-R263L, were
constructed by inserting the entire rat GNE coding region carrying a
point mutation (CGA to CTA) into the KpnI/HindIII site of the
expression vector pcDNA3.1()zeocin. The pcDNA3.1-GNE-R263L
vector was transfected with Lipofectamin (Invitrogen) into a CHO-
EPO cell line, which were prior transfected with a hEPO expression
vector (pKex-cmvEPO) carrying a hygromycin B resistance and
selected with 400 lg/ml hygromycin B for stable production of high
levels of recombinant human EPO (rhEPO). Stable transfected
CHO-EPO-GNE263L clones were isolated after 6 weeks of selection
with 1 mg/ml zeocin.
2.2. Sialic acid quantiﬁcation
Free sialic acid was quantiﬁed by the periodate/resorcinol method
[22]. In brief, lysates from 20 · 106 cells were oxidized in 250 ll with
5 ll of 0.4 M periodic acid at 37 C for 90 min, followed by 15 min
boiling in 500 ll of 6% resorcinol/2.5 mM CuSO4/44% HCl. After
cooling for a few minutes, 500 ll tert-butyl alcohol were added, the
samples were vortexed and centrifuged for 5 min to precipitate cell
debris. Immediately after spinning, the supernatants were poured into
OD cuvettes and read at 630 nm. Sialic acid concentrations were calcu-
lated by comparison with a standard curve.
2.3. Culture of CHO cells
Cells were cultured at 37 C (5% CO2/air) in tissue culture ﬂasks con-
taining alpha-MEM (Biowest) medium and 10% FCS. Hygromycin B
(200 mg/ml) was added to the CHO-EPO cell line culture. Prior 2D-
electrophoresis analysis cells were adapted to serum free CHO-S-
SFM-II (Gibco) medium.
2.4. 2D-electrophoresis
High resolution 2D electrophoresis was performed according to
O’Farrell [23]. In brief, cells were seeded with a cell count of 106 cells
in 10 cm plates with 5 ml CHO-S-SFM-II (Gibco) medium. After 48 h
a 1 mL aliquot of the medium was taken and desalted and concen-
trated to a volume of 50 ml with 5 K NMWL centrifugal ﬁlters
(Millipore). The 50 ml sample was mixed with 320 ml rehydration buf-
fer (2.4 M thiourea, 8.4 M urea, 4.8% CHAPS, 2.4% Immobiline-buﬀer
from Pharmacia, 0.36% DTT) and used to rehydrate Immobiline
Dry Strips (pH 4–7, 11 cm) for 12 h in a rehydration tray. Therehydrated strip was subjected to isoelectric focusing on a MultiPhorII
electrophoresis chamber at the following voltage gradients: 50 V for
12 h, 250 V for 3 h, 1000 V for 1 h, 10000 V for 5 h, and 10000 V
for 6 h (total 88 kV h). After focusing, the strips were incubated in
equilibration buﬀer (10 ml consisting of 6 M urea, 2% SDS, 0.375 M,
pH 8.8, Tris–HCl, 20% glycerol, bromophenol blue) containing 1%
DTT for 10 min, followed by an incubation with equilibration buﬀer
containing 2.5% iodoacetamide for 10 min. The equilibrated IPG strip
was placed onto a 10% polyacrylamide gel and a SDS–PAGE was per-
formed.
2.5. Immunoblotting
The SDS–polyacrylamide gels were transferred to nitrocellulose
ﬁlters. The blots were blocked with 5% fat-free dry milk powder in
PBS, incubated with the EPO (B4)-monoclonal antibody (Santa Cruz
5290), washed with PBS and incubated with the secondary antibodies
(horseradish peroxidase (HRP) conjugated rabbit anti-mouse). After
washing, proteins were detected by enhanced chemiluminescence
(Amersham Buchler) according to the manufacturer’s instructions,
and visualized by exposing the blots to a Fuji imager system (LAS)
for 2 min.
2.6. Proliferation assay
Cells were seeded in 96-well plates at a cell density of 2 · 104 cells per
well in standard medium and incubated for 24 h. The assay was per-
formed as described by Porstman et al. [24] using the cell proliferation
(BrdU) ELISA kit from Roche Diagnostics according to the instruc-
tion manual. The labeling time with BrdU was 3 h and incubation with
anti-BrdU-peroxidase-antibody was for 2 h. Each experiment was per-
formed in quadruplicates.3. Results and discussion
We transfected CHO-K1 cells with rhEPO, using an expres-
sion vector containing a hygromycin-resistance gene to obtain
a cell line producing EPO as our model recombinant protein.
Among the clones, which acquired hygromycin-resistance,
the clone with the highest EPO-expression (CHO-EPO) was
used for the further experiments. These CHO-EPO cells were
then stably transfected with rat GNE-sialuria (R263L), using
the pcDNA3.1-()-zeocin expression vector. A clonal CHO-
Fig. 2. Concentration of sialic acid in CHO-cells. Wild type CHO cells (WT), CHO cells treated with 10 mM ManNAc for 48 h (M), Clone 1–14 of
stable transfected CHO-EPO-sialuria cells (C1–C14). Sialic acid concentration was measured using the periodate/resorcinol method. Bars represent
mean values ± S.D. of three independent experiments carried out in duplicates.
Fig. 3. Immunodetection of EPO after isoelectric focusing of conditioned medium from CHO-EPO cells, CHO-EPO cells supplemented with 10 mM
ManNAc and CHO-EPO-GNE-sialuria (C5) cells. Every spot represents EPO with a diﬀerent pI and a diﬀerent degree of sialylation.
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dilution. To verify the functionality of the sialuria mutation
the free sialic concentration of 14 selected CHO-EPO-sialuria
clones were quantiﬁed, applying the resorcinol/periodic acid
assay (Fig. 2). While the concentration sialic acid of some
clones were in the range of CHO wild type cells (15 fmol/cell),
the majority of clones even exceed the concentration of CHO
cells fed with 10 mM ManNAc for 48 h (40 fmol/cell). The
highest concentration measured was 90 fmol/cell in clone 5
(Fig. 2, C5). This shows that the introduction of GNE with
a defect in the feedback inhibition increases the concentration
of cellular sialic acid at least 6-fold compared to the wild type
cells. Subsequently we determined if this increase of sialic acid
has any inﬂuence on the degree of sialylation of EPO. Two-
dimensional gel electrophoresis is a common method to study
sialylation of glycoproteins. Due to the negative charge of sia-
lic acid a change in the degree of sialylation will lead to a shift
of the isoelectric point (pI) of the sialylated protein while a
lower pI is representing a higher sialylation. Therefore
we performed an isoelectric focusing with a subsequently
immunoblotting, using an anti-EPO antibody (Fig. 3). EPO
expressed by wild type CHO-cells was detected as a large spot
at pH 4.2 and many further spots between pH 5 and 6, corre-
sponding to diﬀerent pIs and representing the diﬀerent degreesof sialylation of EPO. When the CHO-EPO cells were fed with
10 mM of the sialic acid precursor ManNAc to increase the
sialylation, the heterogeneity of the expressed EPO was mark-
edly reduced. Beside the major spot at pH 4.2 there were only
two minor spots around pH 5 detectable. However, we found a
nearly homogenous sialylation when EPO was expressed by
the CHO-EPO-sialuria-cells. Virtually all EPO was in the high
sialylated form with a pI of 4.2 (Fig. 3). This shows that the
overexpression of GNE-sialuria (R263L) can enhance the
sialylation of rhEPO by increasing the intracellular concentra-
tion of free sialic acid and even lead to a higher sialylation then
in ManNAc supplemented cells. For biotechnology use it is
important that the expression of the GNE-Sialuria (R263L)
did not interfere with the growth rate or viability of the
CHO cells. Therefore, we analyzed the proliferation of the
C5 cells with a standard BrdU-assay (Fig. 4) and found that
the proliferation was nearly unchanged. We measured a reduc-
tion by 6.5% compared to the CHO-EPO cells however an
increase by 9.2% compared to CHO-EPO cells which were
supplemented with 10 mM ManNAc.
Taken together, we generated a novel cell line for the expres-
sion of highly sialylated glycoproteins. Since the production of
recombinant glycoproteins has a growing business volume
of more the 40 billion dollar per year we believe that the use
Fig. 4. BrdU-proliferation assay. CHO-EPO cells, CHO-EPO-sialuria cells or CHO-EPO cells supplemented with 10 mMManNAc were analyzed in
the presence or absence of serum (serum-free CHO-cell expression medium). Induction of DNA synthesis was measured by the incorporation of
pyrimidine analogue 5-bromo-2 0deoxyuridine (BrdU), instead of thymidine, into the DNA of proliferating cells. The cells were incubated with BrdU
for 3 h and the incooperation of BrdU into the DNA was detected by immunoassay. At least two experiments were performed in quadruplicates.
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